Disparities in uptake of BRCA1/2 genetic testing in a randomized trial of telephone counseling
Morgan Butrick(National Institutes of Health), Marc D. Schwartz(Guardia Civil), Rachel Nusbaum(Icahn School of Medicine at Mount Sinai), Marie Wood(University of Colorado Cancer Center), Lina Jandorf(Icahn School of Medicine at Mount Sinai), Gillian W. Hooker(National Institutes of Health), Tiffani A. DeMarco(Georgetown University), George Luta(Georgetown University), Wendy McKinnon(University of Vermont), Shelley R. McCormick(Georgetown University), Scott P. Kelly(Pfizer (United States)), Claudine Isaacs(Georgetown University), Kristi D. Graves(Georgetown University), Heiðdís Valdimarsdóttir(Reykjavík University), Beth N. Peshkin(Georgetown University), Lisa Feeley(Georgetown University), Judy E. Garber(Dana-Farber Cancer Institute)
Cited by 95
Related Papers
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Molecular Definition of Breast Tumor Heterogeneity
|Cancer Cell|2007|1.4k